This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schurmans, L. R. H. M. Articles by Jager, M. J. Search for Related Content PubMed PubMed Citation Articles by Schurmans, L. R. H. M. Articles by Jager, M. J.

Successful Immunotherapy of an Intraocular Tumor in Mice¹

Departments of Ophthalmology [L. R. H. M. S., M. J. J.] and Immunohaematology and Blood Bank [A. T. d. B., L. D., E. I. H. v. d. V., C. J. M. M., R. E. M. T.], Leiden University Medical Center, Leiden, P.O. Box 9600, 2300 RC Leiden, the Netherlands, and Cardinal Bernardin Cancer Center, Loyola University of Chicago, 2160 South First Avenue, Maywood, Illinois 60153 [W. M. K.]

Immune privilege in the eye is considered essential in the protection against local sight-threatening inflammatory responses. However, the deviant immune responses in the eye may also provide an ideal opportunity to uncontrolled growth of viruses or tumors by inhibiting intraocular immunological attack. To establish to what extent immune privilege interferes with T cell-mediated antitumor immunotherapy, we established a new ocular tumor model in the mouse and tested whether well-defined tumor-specific CTLs can eradicate an immunogenic intraocularly growing tumor. Tumor cells, transformed by human adenovirus type 5 early region 1 (Ad5E1), injected s.c. in a dose of 10⁷ cells, did not induce s.c. tumor growth in C57BL/6 mice. However, an injection of 0.3 x 10⁶ of these cells into the anterior chamber of the eye led to intraocular tumor growth in 95% of mice (n = 20). Tumor growth in the eye did not induce systemic tumor-specific tolerance, because 70% of the mice were able to eradicate the tumor spontaneously after 5 weeks. Mice vaccinated s.c. with irradiated tumor cells were protected against intraocular tumor challenge, indicating that preactivated memory T cells are able to protect against intraocular tumor growth. Moreover, an i.v. injection of an Ad5E1-specific CTL clone was able to eradicate established intraocular Ad5E1-transformed tumors, whereas the anatomy of the eye remained intact. These results demonstrate that tumor-specific, CTL-mediated immunity can be used successfully for the prevention and eradication of tumors growing in the immune-privileged anterior chamber of the eye, without detectable destruction of the eye.

This article has been cited by other articles:

				D. S. Dace, P. W. Chen, and J. Y. Niederkorn CD8+ T Cells Circumvent Immune Privilege in the Eye and Mediate Intraocular Tumor Rejection by a TNF-{alpha}-Dependent Mechanism J. Immunol., May 15, 2007; 178(10): 6115 - 6122. [Abstract] [Full Text] [PDF]

				D. S. Dace, P. W. Chen, H. Alizadeh, and J. Y. Niederkorn Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner J. Leukoc. Biol., February 1, 2007; 81(2): 421 - 429. [Abstract] [Full Text] [PDF]

				Z. F. H. M. Boonman, L. R. H. M. Schurmans, N. van Rooijen, C. J. M. Melief, R. E. M. Toes, and M. J. Jager Macrophages are vital in spontaneous intraocular tumor eradication. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2959 - 2965. [Abstract] [Full Text] [PDF]

				Z. F. H. M. Boonman, G. J. D. van Mierlo, M. F. Fransen, R. J. W. de Keizer, M. J. Jager, C. J. M. Melief, and R. E. M. Toes Maintenance of Immune Tolerance Depends on Normal Tissue Homeostasis J. Immunol., October 1, 2005; 175(7): 4247 - 4254. [Abstract] [Full Text] [PDF]

				Z. F. H. M. Boonman, G. J. D. van Mierlo, M. F. Fransen, K. L. M. C. Franken, R. Offringa, C. J. M. Melief, M. J. Jager, and R. E. M. Toes Intraocular Tumor Antigen Drains Specifically to Submandibular Lymph Nodes, Resulting in an Abortive Cytotoxic T Cell Reaction J. Immunol., February 1, 2004; 172(3): 1567 - 1574. [Abstract] [Full Text] [PDF]

				L. R. H. M. Schurmans, L. Diehl, A. T. den Boer, R. P. M. Sutmuller, Z. F. H. M. Boonman, J. P. Medema, E. I. H. van der Voort, J. Laman, C. J. M. Melief, M. J. Jager, et al. Rejection of Intraocular Tumors by CD4+ T Cells Without Induction of Phthisis J. Immunol., November 15, 2001; 167(10): 5832 - 5837. [Abstract] [Full Text] [PDF]

				R. P. M. Sutmuller, L. R. H. M. Schurmans, L. M. van Duivenvoorde, J. A. Tine, E. I. H. van der Voort, R. E. M. Toes, C. J. M. Melief, M. J. Jager, and R. Offringa Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp100 J. Immunol., December 15, 2000; 165(12): 7308 - 7315. [Abstract] [Full Text] [PDF]

				S. A. Riemersma, E. S. Jordanova, R. F. J. Schop, K. Philippo, L. H. J. Looijenga, E. Schuuring, and P. M. Kluin Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites Blood, November 15, 2000; 96(10): 3569 - 3577. [Abstract] [Full Text] [PDF]